Clinical Data Boehringer/Zealand dual-acting drug causes 16.6% weight loss PharmaphorumBoehringer/Zealand reveal first phase 3 data with dual GLP-1/glucagon weight-loss drug survodutide.Metabolic & GLP-1Read full story pharminent April 28, 2026 (Last updated: April 28, 2026) Pharmaphorum Boehringer/Zealand reveal first phase 3 data with dual GLP-1/glucagon weight-loss drug survodutide. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: BioMarin acquires Amicus Therapeutics for $4.8bnNext: Seaport and Hemab target $180m IPOs as biotech listings accumulate Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
